Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006350 · ClinicalTrials.gov registry record · Phase 2
Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00006350 is a Phase 2 study that has completed, run by University of Maryland, Baltimore.
The verdict
NCT00006350, a Phase 2 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies such as daclizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation from a brother or sister may be effective treatment for hematologic cancer. Sometimes the transplanted cells can be rejected by the body's tissue. Mycophenolate mofetil, tacrolimus, and donor white blood cells may prevent this from happening. PURPOSE: Phase II trial to study the effectiveness of mycophenolate mofetil, tacrolimus, daclizumab, and donor peripheral stem cell transplantation in treating patients who have hematologic cancer.
Interventions
- DRUG tacrolimus
- PROCEDURE peripheral blood stem cell transplantation
- DRUG mycophenolate mofetil
- BIOLOGICAL therapeutic allogeneic lymphocytes
- BIOLOGICAL daclizumab
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-01 |
| Est. Completion | 2001-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006350
The ClinicalTrials.gov registry entry for NCT00006350 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which tacrolimus is the first listed.
NCT00006350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006350 about?
NCT00006350 is a clinical study titled "Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer". RATIONALE: Monoclonal antibodies such as daclizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation from a brother or sister may be effective treatment for hematologic cancer. Sometimes the tra...
What is the current status of trial NCT00006350?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-01. Estimated completion is 2001-11.
What interventions are being tested in trial NCT00006350?
The interventions under investigation include: tacrolimus (DRUG), peripheral blood stem cell transplantation (PROCEDURE), mycophenolate mofetil (DRUG), therapeutic allogeneic lymphocytes (BIOLOGICAL), daclizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006350?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.